Clinical trials: Influenza, completed
Influenza, Acute Respiratory Infection
Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza
Vaccinating schoolchildren against influenza would prevent the disease among non-vaccinated household members.
- Trial name
- Xo_Gripe (NCT01693380)
- Testing
- Influenza vaccine, Control vaccine
- Where
- Brazil
- Volunteers
- 1,742 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Influenza, Human
Efficacy Study With QIVc in Pediatric Subjects
This phase 3 clinical study is a randomized, observer-blind, multicenter study of QIVc versus a non-influenza vaccine in subjects 6 months though 47 months of age.
- Trial name
- NCT03932682
- Testing
- QIVc, Comparator
- Where
- 74 sites in Bangladesh, Bulgaria and 13 more
- Volunteers
- 5,723 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after…
- Trial name
- NCT00538473
- Testing
- GSK Biologicals' influenza vaccine GSK576389A, Fluarix™
- Where
- Belgium
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pregnancy
Influenza and Text Messaging in Pregnancy
A randomized, controlled clinical trial to assess whether text messaging to an outpatient obstetric population can improve maternal influenza vaccine uptake.
- Trial name
- NCT01248520
- Testing
- influenza and general health information, general health information
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Influenza, Flu
Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine
This phase I-like, open-label, monocenter, descriptive, single-arm clinical safety study will investigate the Shenzhen quadrivalent influenza vaccine (Shz QIV) in 100 participants aged 6 months and older in China.
- Trial name
- NCT03430089
- Testing
- Shz QIV 0.25 mL, 2 doses, Shz QIV 0.5 mL, 2 doses, Shz QIV 0.5 mL, single dose
- Where
- China
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after…
- Trial name
- NCT00538213
- Testing
- Fluarix™, GSK Bio's Influenza Vaccine GSK576389A
- Where
- Belgium
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects
To evaluate the safety, tolerability and pharmacokinetics (PK) of single,and repeat escalating doses of FF-3 dry powder administered via inhalation in healthy adult subjects
- Trial name
- NCT01990846
- Testing
- Flufirvitide 3
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Autoimmune Technologies, LLC
Influenza, Cardiovascular Complication
InFLUenza and the HEART An Investigation Into the Acute and Lasting Cardiac Effects of Influenza Infection
"Influenza and the Heart: An investigation into the acute and lasting cardiac effects of influenza infection" the investigators aim to assess the mechanisms for cardiovascular disease in patients suffering an acute influenza…
- Trial name
- FluHeart (NCT05084846)
- Where
- 2 sites in Denmark
- Volunteers
- 241 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Influenza Vaccines
Active Surveillance for Adverse Events Following Immunization With the Influenza Vaccine Produced at Butantan Institute
Rationale and background: Since 2013, IB has been performing passive pharmacovigilance activities related to TIV. Objetive: To implement an active surveillance study as part of our pharmacovigilance plan while passive…
- Trial name
- FLU-05-IB (NCT03057483)
- Testing
- Seasonal Influenza vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 533 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Influenza
Japanese Pediatric H5N1 Vaccine Study
The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese pediatric population aged 6 months to 17 years
- Trial name
- NCT01911754
- Testing
- H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)
- Where
- 2 sites in Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza, Virus Diseases
Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine
In the 20th century, influenza pandemics occurred in 1918, 1957, and 1968, and were associated with significant morbidity and mortality.
- Trial name
- NCT00722774
- Testing
- H2N2 1960 AA ca recombinant vaccine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers, Influenza Vaccination
A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.
The objective of this study is to evaluate the safety and immunogenicity of different vaccines of hemagglutinin formulations of trivalent influenza vaccine or of a combined respiratory syncytial virus / human metapneumovirus /…
- Conditions
- Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination, Parainfluenza Vaccination
- Trial name
- NCT06850051
- Testing
- TIV-HA Vaccine formulation 1 at low dose, TIV-HA formulation 1 at high dose, TIV-HA formulation 2 at low dose
- Where
- 6 sites in Australia
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Sanofi
Asthma, Chronic Obstructive Pulmonary Disease
Effectiveness of Influenza Vaccine Reminder Systems
Influenza disease causes significant morbidity and mortality in the Unites States each year. Although influenza can cause morbidity in otherwise healthy individuals, adults with chronic lung disease have significantly increased…
- Trial name
- NCT01852656
- Testing
- Postcard and IVR Reminder Group, Postcard Only Reminder Group, IVR Only Reminder Group
- Where
- United States
- Volunteers
- 12,255 people
- Sponsor
- Kaiser Permanente
Heart Failure
Flu Vaccination in Congestive Heart Failure
We evaluated the preventive impact of vaccination on subsequent death events in 117 severe congestive heart patients requiring ventilator support without endotracheal intubations and aggressive medical therapy.
- Trial name
- FLUVACS-IC (NCT00664339)
- Testing
- Flu Vaccine, Conventional medical therapy for heart failure
- Volunteers
- 117 people
- Sponsor
- La Fundacion Favaloro para la Investigacion y la Docencia Medica
Vaccination; Infection, Maternal-Fetal Relations
Maternal Determinants of Immunity to Influenza
The overall objective of the project is to determine the impact of pregnancy on the response to influenza immunization.
- Conditions
- Vaccination; Infection, Maternal-Fetal Relations, Influenza, Immunoglobulins
- Trial name
- MADI-01 (NCT06716567)
- Testing
- Influenza vaccine
- Where
- Belgium
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
SARS-CoV-2, Influenza A
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test
This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 \& Flu A/B tests at point of care sites.
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, Asymptomatic COVID-19
- Trial name
- ITAP1489 (NCT05787444)
- Testing
- LumiraDx SARS-CoV-2 & Flu A/B
- Where
- United States
- Volunteers
- 1,081 people
- Sponsor
- LumiraDx UK Limited
Influenza, Swine-origin A/H1N1 Influenza
A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT00956202
- Testing
- Swine A/H1N1 influenza vaccine (split virion, inactivated), Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
- Where
- 15 sites in Finland
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Immunosuppression
High Dose vs. Standard Influenza Vaccine in Adult SOT
The study will test whether a high dose influenza vaccination results in improved immunogenicity in adult SOT recipients as compared to standard vaccine.
- Trial name
- NCT03139565
- Testing
- Fluzone High-dose Influenza Vaccine, Standard 2016-2017 Flu vaccine
- Where
- Canada
- Volunteers
- 172 people
- Sponsor
- University Health Network, Toronto
Asthma
Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma
Trial to assess asthma exacerbation through to the end of the study; and to demonstrate that the efficacy over one season against culture-confirmed influenza-illness; and finally to assess the safety and tolerability of CAIV-T in…
- Trial name
- NCT00192257
- Testing
- CAIV-T and TIV
- Where
- 2 sites in Belgium
- Volunteers
- 2,229 people
- Sponsor
- MedImmune LLC
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the seasonal quadrivalent influenza vaccine (FLU-QIV) in adults aged 60…
- Trial name
- NCT04841577
- Testing
- RSVPreF3 OA investigational vaccine, FLU-QIV
- Where
- 14 sites in New Zealand, Panama and 1 more
- Volunteers
- 976 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.